secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2021-09-07T23:59:59+00:00
Accession:  0001493152-21-022093
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus reports fully diluted shares of 528.7M as of Sep 7, 2021, down from 563.9M in 2017
--------------------------------------------------------------------------------

- Fully diluted shares outstanding as of Sep 7, 2021: 528,667,356 vs 563,911,848 in 2017.
- Common shares outstanding: 416,575,669; warrants: 512,500; options: 4,800,000; Series D/D-1 conversion shares: 106,779,187.
- All Private Warrants expired by Oct 31, 2020; Listed Warrants expired Jun 23, 2020.
- Convertible notes ($30.56M) converted into Series D/D-1 Preferred on Jun 20, 2021, convertible into ~106.8M common shares.
- Remaining Series B Preferred converted Aug 25, 2021; 13.35M Ratchet Warrants exercised, 68.7M expired by Aug 30, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315221022093/0001493152-21-022093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315221022093/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-022093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer